Status:
COMPLETED
Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)
Lead Sponsor:
Amgen
Conditions:
Kidney Disease
Diabetes Mellitus
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular events, and (2) ...
Eligibility Criteria
Inclusion
- Hemoglobin less than or equal to 11 g/dL
- History of Chronic Kidney Disease
- eGFR (estimated glomerular filtration rate) greater than or equal to 20 mL/min/1.73 m2 and less than or equal to 60 mL/min/1.73 m2
- Tsat (transferrin saturation) greater than 15%
Exclusion
- Uncontrolled hypertension
- Erythropoietic protein use within 12 weeks of randomization
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
4038 Patients enrolled
Trial Details
Trial ID
NCT00093015
Start Date
August 1 2004
End Date
July 1 2009
Last Update
November 8 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.